Xenetic Biosciences reports developments tied to its immuno-oncology programs for difficult-to-treat cancers. The company’s DNase technology targets neutrophil extracellular traps, or NETs, with a systemic DNase program being advanced as an adjunctive approach for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Recurring updates include preclinical and translational research, conference presentations, collaborations with institutional and development partners, and studies evaluating DNase I with chemotherapy, immunotherapies and CAR T-cell approaches. Company news also covers periodic financial results, cash resources, equity financing, shareholder voting matters and other governance developments.
Xenetic Biosciences (XBIO) announced the first patient was dosed in a study combining systemic DNase with CAR T-cell therapy for large B-cell lymphoma.
The investigator-initiated study at Israel's Tel Aviv Sourasky University Medical Center, Xenetic's first clinical evaluation of this combination, is enrolling 12 patients with stable or progressive disease before lymphodepletion therapy. DNase, an enzyme that breaks down DNA, is being evaluated alongside commercial anti-CD19 CAR T-cell therapy. The center sponsors the study, which received Israeli Ministry of Health and institutional review board approval in June 2026. Assessments include objective response rates at one and three months, response duration, disease control and overall survival at 12 months.
Xenetic Biosciences (XBIO) signed a definitive all-stock share exchange agreement to acquire all outstanding share capital of Santersus AG, creating a combined NET-targeting therapeutics company expected to remain Nasdaq-listed and be renamed Santersus Bio with ticker “SNTS.”
Santersus equity holders are expected to own about 85.0% of the combined company and current Xenetic equity holders about 15.0% on a fully diluted, as-converted basis, subject to adjustment based on Xenetic’s closing net cash. The merged entity will focus on neutrophil extracellular traps (NETs) via Santersus’ NucleoCapture blood purification platform and Xenetic’s DNase technology, with a joint pipeline of four first-in-class programs. These include pivotal-stage NucleoCapture programs in sepsis and systemic lupus erythematosus, each with FDA Breakthrough Device Designation, plus programs in liver transplantation and DNase combined with anti-CD19 CAR-T cells for large B-cell lymphoma. Closing is targeted for Q4 2026, subject to Xenetic stockholder approval, Nasdaq listing of new shares, S-1 effectiveness and other customary conditions.
Xenetic Biosciences (NASDAQ: XBIO) reported second quarter 2026 results and reiterated progress on its proprietary DNase platform in immuno-oncology. Royalty revenue for the three months ended June 30, 2026 rose about 12% to approximately $0.7 million, driven primarily by higher royalties under its sublicense agreement with Takeda. Research and development expenses declined roughly 16% to about $0.6 million, while general and administrative expenses increased around 64% to approximately $1.1 million, mainly due to legal costs related to an ongoing strategic review. Net loss for the quarter was about $0.9 million versus approximately $0.7 million a year earlier, and cash and cash equivalents totaled roughly $6.5 million at June 30, 2026, compared to about $7.9 million at December 31, 2025.
Operationally, Xenetic highlighted positive preclinical and translational data presented at ASCO 2026 showing DNase I enhanced CAR T-cell expansion, persistence, tumor control and survival in hematologic cancer models, expansion of collaborative research on DNase-mediated NET targeting, and approximately $1.5 million in royalty revenue generated in the first half of 2026.
Xenetic Biosciences (NASDAQ: XBIO)/b) reported that collaboration partner PeriNess received approval from the Israeli Ministry of Health and an Institutional Review Board for an exploratory, investigator-initiated study of systemic with anti-CD19 CAR T cells in large B-cell lymphoma (LBCL).
The single-center trial at Tel-Aviv Sourasky Medical Center plans to treat 12 LBCL patients with stable or progressive disease using approved anti-CD19 CAR T products plus DNase I, assessing response rates, disease control and overall survival, supported by prior preclinical data showing enhanced CAR T activity.
Xenetic Biosciences (NASDAQ: XBIO) reported new preclinical and translational data showing that DNase I enhanced CAR-T cell expansion, persistence, tumor control, and survival in aggressive B cell malignancy models. Data, including results from NALM-6 and Raji xenografts and a pediatric Burkitt lymphoma case, are being presented at ASCO 2026.
Xenetic Biosciences (NASDAQ: XBIO) reported first quarter 2026 results and progress on its DNase I oncology platform. Royalty revenue rose about 36% to $0.8 million, while research and development and general and administrative expenses declined.
Net loss fell to $0.5 million, with $7.3 million in cash as the company evaluates strategic alternatives.
Xenetic Biosciences (NASDAQ:XBIO) announced an abstract acceptance for presentation at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago.
The poster, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," will be presented June 1, 2026, 9:00 AM–12:00 PM CDT (Poster Board 410) by Alexey V. Stepanov, PhD, in the Hematologic Malignancies - Plasma Cell Dyscrasia session.
Xenetic Biosciences (NASDAQ:XBIO) reported full-year 2025 results and scientific progress on its DNase I immuno-oncology program. Key points: net loss of $2.7 million, royalty revenue up ~19% to $3.0 million, and year-end cash of $7.9 million. The company advanced preclinical, translational and IND-enabling activities and supported investigator-initiated trials in PDAC and proposed LBCL/CAR-T combinations.
Xenetic Biosciences (NASDAQ:XBIO) announced its 2025 Annual Meeting of Stockholders was convened and adjourned on December 11, 2025 due to a lack of quorum.
The meeting will reconvene virtually at 10:00 a.m. ET on Thursday, January 8, 2026. The record date for voting remains October 15, 2025. Stockholders who already voted do not need to re-submit votes; previously submitted proxies remain valid unless revoked.
Stockholders who have not voted are urged to vote by 11:59 p.m. ET on January 7, 2026 via www.proxyvote.com or telephone 1-800-690-6903. Broker-held shares may have earlier deadlines. The reconvened meeting can be attended at http://www.virtualshareholdermeeting.com/XBIO2025.
Xenetic Biosciences (NASDAQ:XBIO) executed a 4-month extension of its R&D collaboration with Scripps Research and Dr. Alexey Stepanov effective November 1, 2025 to advance its systemic DNase I program (XBIO-015) in combination with CAR-T therapies.
Preclinical studies in lymphoma, metastatic melanoma and leukemia models reported that co-administration of DNase I with CAR-T cells reduced tumor burden, decreased metastatic lesions, increased CAR-T and endogenous T-cell tumor infiltration, and extended survival versus CAR-T monotherapy. Xenetic says the program has progressed from proof-of-concept to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial targeting pancreatic carcinoma and other advanced solid tumors.